Securities Report – 5th Period (2025/04/01 – 2026/03/31)

Sawai Group Holdings Co., Ltd. Securities Report – 5th Period (2025/04/01 – 2026/03/31)

This document is the Securities Report for the 5th period (April 1, 2025 – March 31, 2026) submitted by Sawai Group Holdings Co., Ltd. in accordance with the Financial Instruments and Exchange Act. As a publicly listed company, this report fulfills our disclosure obligations and provides investors and market participants with critical information, including financial condition, business performance, corporate governance, and future outlook.

Our mission is to contribute to patient health and improved medical quality through pharmaceutical research, development, manufacturing, and distribution. Responding to healthcare needs both in Japan and abroad, we maintain a broad portfolio of products, with a focus on generic medicines. Moving forward, we will continue to strengthen R&D, improve production efficiency, and expand globally to achieve sustainable growth.

For further details of this report, please visit the company's official website or the Financial Services Agency's EDINET system.